Find policies, billing codes, payers, states, and providers
Chelation Therapy for Off-Label Uses
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Blue Cross Blue Shield - Rhode Island coverage stance for chelation therapy when used for non–FDA-approved indications and applies to Commercial Products (not Medicare Advantage). Affects providers submitting claims and members seeking chelation for listed off-label conditions.
No material clinical or coverage changes in this revision.
Coverage Criteria — Chelation Therapy
Not Medically Necessary – Off-label Indications
Off-label uses considered not medically necessary
Applies to listed conditions and similar off-label uses; this policy does not address FDA‑approved indications such as lead poisoning, transfusional hemosiderosis, Wilson disease, emergency hypercalcemia, or digitalis‑related arrhythmia treatment; see related Medicare Advantage policy for those members.
Benefit Variability
Coverage notes
This policy applies to Commercial Products only; Medicare Advantage members should refer to the related Medicare Advantage policy and applicable National and Local Coverage Determinations.
This policy does not address FDA-approved indications for chelation therapy which remain standard of care. Excluded, FDA-approved uses include management of ventricular arrhythmias or heart block from digitalis toxicity, emergency treatment of hypercalcemia, extreme conditions of metal toxicity, lead poisoning, treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) or non-transfusion-dependent thalassemia, and Wilson disease (hepatolenticular degeneration). The policy applies to Commercial Products only; see the related Medicare Advantage section for Medicare-related guidance.
The HCPCS code M0300 (IV chelation therapy — chemical endarterectomy) and any medications used as part of that service are considered not medically necessary when billed with the ICD-10 diagnosis codes listed in this policy. Providers must report chemical endarterectomy using code M0300 when applicable; failure to report appropriately will be considered improper coding and may prompt claim denial or coding review.
Coverage and payment determinations are governed by the member's subscriber agreement or employer agreement, which supersede this medical policy. For member-specific benefits and eligibility, providers should contact the provider call center. This policy is informational and is not a guarantee of payment.
Off-label applications of chelation therapy — defined here as non–FDA-approved uses — are considered not medically necessary for Commercial Products. Specific off-label indications listed include Alzheimer disease; arthritis (including rheumatoid arthritis); atherosclerosis (eg, coronary artery disease or secondary prevention after myocardial infarction); autism spectrum disorder; diabetes; multiple sclerosis; and Parkinson disease. The evidence is insufficient to demonstrate a net health benefit for these uses, and coverage for these indications is therefore not recommended under this policy.
When services are determined to be not medically necessary or are non-covered benefits under the member's contract, providers may not charge the member for those services unless the member has been informed in advance and has provided written agreement to self-pay. Providers should consult participation agreements for applicable billing provisions and confirm benefit responsibility with the provider call center prior to delivering services that may be excluded from coverage.
Coding and Billing
| S9355 | Home Infusion Therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
| M0300 | IV chelation therapy (chemical endarterectomy) |
| E08.00-E13.9 | Diabetes mellitus range (ICD-10 code block listed) |
| F84.0-F84.9 | Pervasive developmental disorders including autism spectrum disorder (ICD-10 code block listed) |
| G20.A1-G20.A2 | Parkinson disease related codes (as listed) |
| G20.B1-G2 | Parkinson disease related codes (as listed) |
| G20.C | Parkinson disease related code (as listed) |
| G21.4 | Secondary Parkinsonism code (as listed) |
| G21.8-G21.9 | Other secondary Parkinsonism codes (as listed) |
| G30.0-G30.9 | Alzheimer disease codes (ICD-10 code block listed) |
| G35.A-G35.D | Multiple sclerosis related codes (as listed) |
| I25.10-I25.9 | Atherosclerotic heart disease codes (ICD-10 code block listed) |
Provider Actions & Billing Guidance
Prior authorization not applicable
No prior authorization is required under this off‑label chelation policy; coverage for services is determined by the member’s benefit booklet, Evidence of Coverage, or subscriber agreement.
- Coverage decisions depend on the applicable contract/benefit booklet.
Verify prior authorization and member coverage
The policy does not specify prior authorization codes or a formal prior‑auth process. Providers should verify member coverage and any prior authorization requirements with the provider call center or via applicable participation agreements.
- Confirm member‑specific prior authorization requirements with the provider call center.
- Refer to participation agreements for contractual obligations.
Expect denials for off‑label chelation indications
Off‑label chelation therapies listed in this policy are considered not medically necessary for Commercial Products and may be denied when billed for those indications.
- Listed indications include Alzheimer disease; arthritis (including rheumatoid arthritis); atherosclerosis/coronary artery disease; autism spectrum disorder; diabetes; multiple sclerosis; and Parkinson disease.
- Refer to the member’s Benefit Booklet/Evidence of Coverage for contract‑specific determinations.
Do not bill member without written consent for non‑covered services
If services are determined to be not medically necessary or non‑covered under the member’s contract, the provider may not bill the member unless the member provided written informed agreement to self‑pay in advance.
- Obtain and document written member agreement before collecting payment for non‑covered or not medically necessary services.
Billing: S9355 represents infusion service only
When billing infusion services, use HCPCS S9355 for the infusion service only; drugs and nursing visits must be coded and billed separately and S9355 is not separately reimbursed.
- S9355 — Home Infusion Therapy, chelation therapy; infusion service only (drugs and nursing visits coded separately), per diem.
- Benefits and reimbursement may vary by contract; refer to the Benefit Booklet.
Verify benefits and eligibility before providing services
Verify member‑specific benefits and eligibility with the provider call center prior to providing services; benefits and coverage are defined by the member’s subscriber agreement or employer agreement and may supersede this policy.
- Contact the provider call center for member‑specific coverage information.
- Review the member’s Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable coverage rules.
Off‑label chelation is not medically necessary for listed indications
Off‑label chelation therapies for the listed indications are considered not medically necessary for Commercial Products and may be denied; coverage decisions are ultimately governed by the member’s contract.
- Services for non‑FDA‑approved indications (eg, Alzheimer disease, arthritis, atherosclerosis, autism, diabetes, MS, Parkinson disease) are not medically necessary per this policy.
- Always confirm contract‑level coverage in the Benefit Booklet/Evidence of Coverage.
Report Chemical Endarterectomy with M0300
Participating providers must report Chemical Endarterectomy using HCPCS code M0300 when applicable; failure to do so will be considered improper coding and may trigger denial or coding review.
Member financial liability when services are non‑covered or not medically necessary
If services are determined to be not medically necessary or are non‑covered benefits, claims may be denied and providers may not collect payment from the member unless the member provided written advance agreement to self‑pay.
- Confirm member financial responsibility only after obtaining written informed consent for self‑payment.
- Denials for not medically necessary services follow contract terms.
Background and Scope
Chelation therapy works by administering agents that bind metal ions to facilitate their excretion, reducing body burden of metals. It is an established therapy for acute metal toxicities and for management of chronic iron overload from transfusions (transfusional hemosiderosis). Investigational approaches, including agents described as metal protein attenuating compounds (MPACs), target metal interactions in the brain rather than systemic metal removal. The evidence base for most off-label indications consists of small randomized trials and observational series and is insufficient to establish a clear net health benefit for the non–FDA-approved uses listed in this policy.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.